Important information

You are about to visit a website set up by NextCell Pharma AB (publ) for the purpose of publishing documents and information about its forthcoming new issue of shares. In order to access additional information, visitors need to confirm that the following information has been read and accepted.

Disclaimer

Due to legal restrictions, this section of the website for NextCell Pharma AB (publ) (the “Company”) is not available for some persons. We therefore kindly ask you to read the following information and to confirm the following every time you with to access this website. Please note that the conditions below may be subject to change or updates and that it is important that you read them every time you visit this page.

The information on this website is not intended for, and must not be accessed by, or released, distributed or presented, directly or indirectly, wholly or partially, to persons residing or physically present in the USA (including its territories and possessions, any state of the USA and the District of Columbia) (the “USA”), Australia, Canada, New Zealand, Hong Kong, Japan, South Korea, Singapore, Schweiz, South Africa or any other jurisdiction where such activities wholly or partially are subject to legal restrictions, or that would require additional prospectus, registration or other measures than those required under Swedish law. Information on the websites does not constitute an offer regarding shares, paid and subscribed interim shares, subscription rights or any other securities issued by the Company (“Securities”) to any person in said jurisdictions. The information on the websites may not be forwarded or reproduced in a way that might violate such restrictions or be subject to such requirements.

No Securities have been registered or will be registered under the United States Securities Act of 1933, as amended, or under the securities regulation in any state or any jurisdiction in the USA and may not be offered, subscribed, exercised, pledged, sold, distributed, allotted, delivered or in any other way transferred, directly or indirectly, in or into the USA, except from when done in accordance with any exemption accepted by the Company.

The Company reserves the right to, in accordance with any applicable exemption, accept subscription from a person present in or residing in a jurisdiction where participation otherwise would require additional prospectus, registration or other measures than those required under Swedish law.

No public offering of Securities is made to any country within the European Economic Area (the “EEA”) other than Sweden. In other member states of the European Union (the “EU”), such offer may only be made in un accordance with exemptions in the prospectus regulation (EU) 2017/1129 (the “Prospectus Regulation”). In other member states of the EEA which have implemented the Prospectus Regulation into national law such offering may be made only under the exemptions of the Prospectus Regulation and relevant implementation measures. In other countries within the EEA not having implemented the Prospectus Regulation into national law, such offer may only be made in accordance with applicable exemptions in national law.

To access the information contained in this section of the Company’s website, all persons must first ensure that they are not subject to legal restrictions that limit their right to access the information in this section of the Company’s website.

We therefore kindly ask you to confirm that you are resident or physically present outside the USA, Australia, Canada, New Zealand, Hong Kong, Japan, South Korea, Singapore, Schweiz, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required under Swedish law, and are entitled to access the information on these websites without being subject to restrictions in any law or other regulations and without any further action being required by the Company. We also kindly ask you to confirm that you have read the information, conditions and restrictions above, and confirm that you agree to comply with these.

Rights Issue

Here you will find the prospectus and application forms for the Rights Issue

Documents to download